eFFECTOR Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 9:30 AM ET. CEO Steve Worland will host 1x1 meetings and a presentation link is available here. eFFECTOR focuses on selective translation regulator inhibitors (STRIs) for cancer treatment, with tomivosertib in Phase 2b trials for NSCLC and zotatifin in Phase 2a studies for biomarker-positive tumors and COVID-19. A live webcast will be accessible post-event on their website.
- None.
- None.
SAN DIEGO and REDWOOD CITY, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Investment Conference.
| Presentation Date: | Monday, September 12, 2022 |
| Time: | 9:30 AM ET |
| Presenter: | Steve Worland, Ph.D., President and Chief Executive Officer |
| Presentation Link: | https://journey.ct.events/view/f2daafbf-6fa4-4087-9078-8140c7335ffa |
| Conference Website | https://hcwevents.com/globalconference/ |
A live webcast will be available on the "Events and Presentation" page of the Investors section of the Company’s website at www.effector.com. A replay of the webcast will be available for 30 days following the event. For more information, please visit https://investors.effector.com/.
About eFFECTOR Therapeutics
eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of a network of functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. In addition to the company’s oncology focus, zotatifin is being evaluated as a potential host-directed anti-viral therapy in patients with mild to moderate COVID-19 in collaboration with the University of California, San Francisco, under a
Contacts:
| Investors: | Media: | |
| Christopher M. Calabrese Managing Director LifeSci Advisors 917-680-5608 ccalabrese@lifesciadvisors.com | Kevin Gardner Managing Director LifeSci Advisors 617-283-2856 kgardner@lifesciadvisors.com | Heidi Chokeir, Ph.D. Managing Director Evoke Canale 619-203-5391 Heidi.chokeir@evokegroup.com |
FAQ
What is eFFECTOR Therapeutics presenting at the H.C. Wainwright Conference?
When is eFFECTOR's presentation at the H.C. Wainwright Conference?
Who is presenting for eFFECTOR at the H.C. Wainwright Conference?
How can I access eFFECTOR Therapeutics' presentation?
What are the key products being discussed by eFFECTOR Therapeutics?
What is the focus of eFFECTOR Therapeutics?
